Dyskeratosis Congenita

  • Vineeta Gupta
  • Akash Kumar
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 685)


Dyskeratosis congenita (DC) is an inheritable bone marrow failure syndrome characterized by reticulated hyperpigmentation, dystrophic nails and oral leukoplakia. Another name for the condition is Zinsser-Cole-Engman syndrome. Hematologic manifestations usually do not appear in childhood but later in early adulthood. Patients are also prone to carcinomas, particularly of the head and neck. The disease has X-linked or autosomal dominant/recessive inheritance. Early childhood variants (Hoyeraal-Hreidarsson syndrome) are associated with immunological abnormalities in the form of low T- and B-cell numbers. Four genes, namely DKC1 (codes for dyskerin), TERC and TERT (code for telomerase) and NOP10, have been implicated in the pathogenesis; the short telomeres provide a marker for genetic linkage studies. Androgens, with or without granulocyte colony stimulating factor, have been tried in the treatment of the conditions with variable results. Stem cell transplantation from matched sibling donor is currently the treatment of choice. It requires modified nonmyeloablative conditioning protocols, since the patients with DC are prone to pulmonary and hepatic complic


Aplastic Anemia Fanconi Anemia Bone Marrow Failure Short Telomere Dyskeratosis Congenita 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alter BP. Bone marrow failure syndrome in children. Pediatr Clin North Am 2002; 49:973–988.PubMedCrossRefGoogle Scholar
  2. 2.
    Alter BP, Potter NU, Li FP. Classification and etiology of the aplastic anaemias. Clin Haematol 1978; 7:431–465.PubMedGoogle Scholar
  3. 3.
    Windass B, Vowels MR, O’Gorman Hughes D. Aplastic anemia in childhood: Prognosis and approach to therapy. Med J Aust 1987; 146:15–19.PubMedGoogle Scholar
  4. 4.
    Gupta V, Tripathi S, Singh TB et al. A study of bone marrow failure syndrome in children. Indian J Med Sci 2008; 62:13–18.PubMedCrossRefGoogle Scholar
  5. 5.
    Tamary H, Alter BP. Current diagnosis of inherited bone marrow failure syndrome. Pediatr Hematol Oncol 2007; 24:87–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Alter BP. Diagnosis, genetics and management of inherited bone marrow failure syndrome. Hematology Am Soc Hematol Educ Program 2007; 29–39.Google Scholar
  7. 7.
    Gupta V, Bhatia BD. Dyskeratosis congenita Indian Pediatr 2008; 45:936.PubMedGoogle Scholar
  8. 8.
    Ahmad, SI, Kirk. SH. eds. Molecular Mechanisms of Fanconi anemia. Austin/New York: Landes Bioscience/ Springer Science/Business Media Inc., 2006.Google Scholar
  9. 9.
    Mitchell JR Wood E, Collins K. A telomere component is defective in the human disease: Dyskeratosis Congenita. Nature 1999; 402:551–555.PubMedCrossRefGoogle Scholar
  10. 10.
    Vulliamy TJ, Marrone A, Dokal I et al. Association between aplastic anemia and mutations in telomerase RNA. Lancet 2002; 359:2168–2170.PubMedCrossRefGoogle Scholar
  11. 11.
    Vulliamy TJ, Marrone A, Knight SW et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107:2680–2685.PubMedCrossRefGoogle Scholar
  12. 12.
    Ortega JA, Swanson VL, Landig BH et al. Congenital Dyskeratosis: Zimmer-Engman-Cole syndrome with thymic dysplasia and aplastic anemia. Am J Dis Child 1972; 124:701–704.PubMedGoogle Scholar
  13. 13.
    Lee BW, Yap HK, Quah TC et al. T-cell immunodeficiency in Dyskeratosis Congenita. Arch Dis Child 1992; 67:524–526.PubMedCrossRefGoogle Scholar
  14. 14.
    Knudson M, Kulharni S, Ballas ZK et al. Association of immune abnormalities with telomere shortening in autosomal dominant DC. Blood 2005; 105:682–688.PubMedCrossRefGoogle Scholar
  15. 15.
    Cossu F, Vulliamy TJ, Marrone A. A novel DKCI mutation, severe combined immunodeficiency (T+B-NK-SCID) and BHT in and infant with Hoyeraal-Hreidarsson syndrome. Br J Haematol 2002; 119:765–768.PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta V, Bhatia BD. Immunological abnormalities in Dyskeratosis congenita. Indian Pediatr 2009; 46:448.Google Scholar
  17. 17.
    Giri N, Pitel N, Green D. Splenic peliosis and rupture in patients with Dyskeratosis congenita on androgens and G-CSF. Br J Haematol 2007; 138:815–817.PubMedCrossRefGoogle Scholar
  18. 18.
    Connoli P, Basso S, Huanga GC. Intensive immunosuppression therapy for aplastic anemia associated with Dyskeratosis congenita: report of a case. Int J Hematol 2006; 83:275–276.CrossRefGoogle Scholar
  19. 19.
    de La Fuente J, Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007; 11:584–594.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  1. 1.Department of Pediatrics, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations